首页> 美国卫生研究院文献>Stem Cells Translational Medicine >Progenitor cell therapy for acquired pediatric nervous system injury: Traumatic brain injury and acquired sensorineural hearing loss
【2h】

Progenitor cell therapy for acquired pediatric nervous system injury: Traumatic brain injury and acquired sensorineural hearing loss

机译:祖细胞疗法用于获得的儿科神经系统损伤:创伤性脑损伤和获得的感官听力损失

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

While cell therapies hold remarkable promise for replacing injured cells and repairing damaged tissues, cell replacement is not the only means by which these therapies can achieve therapeutic effect. For example, recent publications show that treatment with varieties of adult, multipotent stem cells can improve outcomes in patients with neurological conditions such as traumatic brain injury and hearing loss without directly replacing damaged or lost cells. As the immune system plays a central role in injury response and tissue repair, we here suggest that multipotent stem cell therapies achieve therapeutic effect by altering the immune response to injury, thereby limiting damage due to inflammation and possibly promoting repair. These findings argue for a broader understanding of the mechanisms by which cell therapies can benefit patients.
机译:虽然细胞疗法对更换损伤细胞并修复受损的组织来保持显着的承诺,但细胞更换不是这些疗法可以达到治疗效果的唯一方法。例如,最近的出版物表明,用成年人的品种治疗,多能干细胞可以改善神经病症患者的结果,例如创伤性脑损伤和听力损失,而无需直接取代受损或丢失的细胞。由于免疫系统在损伤反应和组织修复中起着核心作用,我们在此表明​​,多能干细胞疗法通过改变对损伤的免疫应答来实现治疗效果,从而限制由于炎症和可能促进修复造成的伤害。这些调查结果争论更广泛地理解细胞疗法可以使患者受益的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号